92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER
Oral Cavity Carcinoma
Masonic Cancer Center, University of MinnesotamixtureN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Oral Cavity Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Vrp-Encapsulated Sarna Encoding Il-12 VLP Therapeutics | Phase 1 | CC |
Pembrolizumab VLP Therapeutics | Phase 1 | CC |
Same molecule, other indications
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →